clinical trial · NCT06476808
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Bristol-Myers Squibb·phase1·recruiting·n = 240
High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)Non-small Cell Lung Cancer (NSCLC)BMS-986463
brief summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
started
Sep 6, 2024
primary completion
Dec 19, 2028
completion
Dec 19, 2028
last updated
Apr 15, 2026
official title
A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol